May 26, 2016

Sponsored by
Eurofins Pharma Bioanalytical Services logo



Webinar Description:

Matrix Interference in Ligand-Binding Assays: Modern Solutions to an Established Analytical Problem. Matrix interference refers to any factor in the sample matrix – ie, serum, plasma, CSF – that can cause an inaccurate result. Matrix interference is among the most common causes of failed validations and anomalous sample data when using ligand-binding assays. These matrix effects may be caused by non-specific, drug-specific or disease state-specific factors. In this session we will discuss the possible causes of matrix interference, the impact on assay performance, methods of evaluating matrix effects, and potential approaches to resolve or avoid matrix interference.

Learning Objectives:

  • Sources of matrix interference in immunoassays
  • Types of matrix interference
  • How to identify matrix interference with assay performance
  • Techniques to mitigate the effects of matrix interference


John KamerudJohn Kamerud, PhD.

Scientific Director

Eurofins Pharma Bioanalytical Services

Dr. Kamerud is Scientific Director at Eurofins’ St Charles, Missouri site, where he serves as scientific and technical advisor for both clients and internal teams for development, validation, and application of assays to comply with scientific goals and regulatory requirements. He received his PhD (Biochemistry) degree in 1987 from the University of Minnesota. Dr Kamerud has over 20 years of experience in the development, validation and implementation of immunoassay methods, holding positions with EMD Millipore, Covance Laboratories and Eli Lilly and Company.